GIPC2

Across TCGA pan-cancer cohorts, GIPC2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GIPC2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GIPC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GIPC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, UCEC, and GBM are the cancer types where GIPC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.688	<.001	48	view →
UCEC	DFS	Median	II,III,IV	1.000	0.432	.006	24	view →
GBM	DFS	Median	All	0.043	0.257	<.001	12	view →
BRCA	DFS	Median	All	0.358	0.903	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GIPC2–STAD (OS)

Open the STAD breakdown →